JSC “Grindeks” announced that it has completed the Phase 1 clinical study of its new investigational medicinal product metyl-GBB. This new investigational medicinal product is intended for the treatment of cardiovascular diseases. This treatment will have a unique therapeutic advantage –the new medicine will be available in both parenteral and oral dosage forms. Preclinical studies have demonstrated the efficacy of the new molecule in reducing heart infarct size as a result of mitochondrial protection, attenuation of atherosclerosis progression and improving glucose metabolism. Preclinical and clinical Phase 1 studies show a very good safety profile of the investigational medicinal product. Phase 1 clinical study was conducted in collaboration with internationally renowned researchers, scientific consultants and contract research organizations in accordance with the “Good Clinical Practice” (ICH /GCP) and European Union regulatory requirements for Phase I - IV clinical trials.